NCT01342198View on ClinicalTrials.gov

An Investigation of the Effects of Erythromycin on the Pharmacokinetics of the Pregabalin Controlled Release Tablet

PHASE1CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

June 30, 2011

Primary Completion Date

July 31, 2011

Study Completion Date

July 31, 2011

Conditions
Healthy
Interventions
DRUG

Pregabalin controlled release, 330 mg

A single oral dose of 330 mg controlled release tablet

DRUG

Pregabalin controlled release, 330 mg

A single oral dose of 330 mg controlled release tablet

DRUG

erythromycin

A total of three doses of 500 mg erythromycin ethylsuccinate tablets administered six hours apart beginning approximately 1 hour prior to pregabalin CR

Trial Locations (1)

B-1070

Pfizer Investigational Site, Brussels

All Listed Sponsors
lead

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

INDUSTRY

NCT01342198 - An Investigation of the Effects of Erythromycin on the Pharmacokinetics of the Pregabalin Controlled Release Tablet | Biotech Hunter | Biotech Hunter